T Cell News and Research

Latest T Cell News and Research

CLL patients receive Biothera's new combination therapy in Phase I/II clinical trial

Patients with earlier stage high-risk Chronic Lymphocytic Leukemia recently began receiving a new combination treatment in a Phase I/II clinical trial that researchers believe could result in a more effective therapy for this disease, Biothera announced today.

15 Mar 2011

Researchers discover new key component in lung cancer spread

Researchers discovered a new, key component in the spread of lung cancer as well as a likely way to block it with drugs now in clinical trial. The study was published today (Monday, March 14) in the Journal of Clinical Investigation.

15 Mar 2011

OncoSec signs agreement with Inovio to purchase non-DNA cancer vaccine technology

OncoSec Medical Inc., a developer of innovative and proprietary medical approaches to treat solid tumor cancers with unmet medical needs, announced today that it has signed an agreement with Inovio Pharmaceuticals, Inc. providing for the purchase by OncoSec of certain non-DNA vaccine technology and intellectual property relating to electroporation technology useful for electrochemical and cytokine based immune therapies for treating solid tumors.

15 Mar 2011

Specific inflammatory factor may be responsible for aortic stenosis development

Research from Karolinska Institutet in Sweden shows that a specific inflammatory factor may be important in the development of the heart valve disease aortic stenosis. The results suggest that anti-inflammatory medication could be a possible new treatment.

15 Mar 2011

Scientists identify unique function of Twist1 in tumor metastasis

In the early stages of human embryogenesis, a transcription factor called Twist1 plays a key regulatory role in how the embryo assumes form and function. Much later in life, however, researchers at the University of California, San Diego School of Medicine, say Twist1 can re-emerge, taking a darker and more deadly turn.

15 Mar 2011

Cellpraxis, USF Health, UNIFESP present and evaluate ReACT results at scientific meeting

Cellpraxis, USF Health and UNIFESP presented and evaluated the clinical results of an innovative therapy for Refractory Angina patients in a scientific meeting and workshop in São Paulo, Brazil.

15 Mar 2011

Researchers develop novel system to show how specific mutations can induce glioblastoma

Mutations in three pathways important for suppressing tumors cooperate to launch glioblastoma, an aggressive brain tumor that strikes children and adults. But new research from St. Jude Children's Research Hospital scientists shows those changes alone are not sufficient to cause cancer.

15 Mar 2011

Challenge Problems in mathematical cardiology

Did you know that heart attacks can give you mathematics? That statement appears on the web site of James Keener, who works in the mathematics of cardiology. This area has many problems that are ripe for unified attack by mathematicians, clinicians, and biomedical engineers.

15 Mar 2011

Covidien to present new data on hernia, abdominal wall repair products at San Francisco

Covidien, a leading global provider of healthcare products, announced that new data on its hernia and abdominal wall repair products will be presented at Hernia Repair 2011, the 14th Annual Meeting & Scientific Program of the American Hernia Society.

15 Mar 2011

New research: Fzd9 receptor can stimulate bone formation

New research shows that the Wnt receptor Frizzled-9 promotes bone formation, providing a potential new target for the treatment of osteoporosis. The study appears online on March 14 in The Journal of Cell Biology.

15 Mar 2011

Scientists identify strategy for targeted molecular therapy in liver cancer

In a research study appearing in the journal Cancer Cell on March 14, scientists from Cold Spring Harbor Laboratory and four other institutions have identified a strategy for targeted molecular therapy in liver cancer, which currently has limited treatment options and one of the worst one-year survival rates of any cancer type.

15 Mar 2011

New findings may open doors for vaccine development against HIV, tuberculosis

Alum is an adjuvant used in many common vaccines, and Canadian researchers have now discovered how it works. The research by scientists from the University of Calgary's Faculty of Medicine is published in the March 13 online edition of Nature Medicine.

15 Mar 2011

EC grants marketing authorization for Taiho's Teysuno to treat gastric cancer

Taiho Pharmaceutical Co., Ltd., and its parent company, Otsuka Holdings Co., Ltd., announced today that the European Commission has granted marketing authorization for Teysuno, a novel oral anti-cancer agent indicated for the treatment of adults with advanced gastric cancer when given in combination with cisplatin.

15 Mar 2011

New animal model helps define molecular processes that lead to PA

Pilocytic astrocytoma is the most common pediatric brain tumor, and there are few medical therapies available to those patients for whom surgery is not curative.

15 Mar 2011

Nanoscale whiskers could hold key to creating working human muscle tissue

Minute whiskers of nanoscale dimensions taken from sea creatures could hold the key to creating working human muscle tissue, University of Manchester researchers have discovered.

14 Mar 2011

How male puberty begins

Scientists from Monash University have uncovered a new understanding of how male puberty begins.

14 Mar 2011

HemaCare reports $7.0 million revenue for fourth quarter 2010

HemaCare Corporation announced today that the Company generated fourth quarter revenue of $7.0 million and a net loss of $197,000, or $0.02/share, compared to fourth quarter 2009 revenue of $8.2 million and net income of $195,000, or $0.02/share.

14 Mar 2011

Researchers discover new gene for Sensenbrenner syndrome

Dutch researchers of the Radboud University Medical Center in Nijmegen found a new gene for Sensenbrenner syndrome (Journal of Medical Genetics, 2011 Mar 4). The mutation adds support to the hypothesis that defects in ciliar transport are the cause of the disease. Project leader Dr. Heleen H. Arts is supported by a Kolff Junior Postdoc Grant of the Dutch Kidney Foundation.

14 Mar 2011

European Patent Office grants ProtAffin key patent for CellJammer discovery technology

ProtAffin AG, a biotechnology company developing novel biopharmaceuticals for respiratory disease, inflammation and oncology, today announced that it has been granted a key patent by the European Patent Office protecting its CellJammer® discovery technology, which enables the development of a new class of biopharmaceuticals.

14 Mar 2011

ChronTech initiates ChronVac-C DNA vaccine Phase IIb study against HCV

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that its partner, ChronTech Pharma AB, has initiated a Phase IIb clinical study of its ChronVac-C DNA vaccine for hepatitis C virus, delivered by Inovio's proprietary electroporation DNA vaccine delivery technology, in combination with standard of care.

14 Mar 2011